BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3547951)

  • 21. Transplantation of T lymphocyte depleted bone marrow to prevent graft-versus-host disease: its implications for fetal liver transplantation.
    Champlin RE; Mitsuyasu RT; Gale RP
    Prog Clin Biol Res; 1985; 193():315-25. PubMed ID: 3911215
    [No Abstract]   [Full Text] [Related]  

  • 22. HLA nonidentical T cell depleted marrow transplants: a comparison of results in patients treated for leukemia and severe combined immunodeficiency disease.
    O'Reilly RJ; Keever C; Kernan NA; Brochstein J; Collins N; Flomenberg N; Laver J; Emanuel D; Dupont B; Cunningham I
    Transplant Proc; 1987 Dec; 19(6 Suppl 7):55-60. PubMed ID: 3321647
    [No Abstract]   [Full Text] [Related]  

  • 23. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT.
    Bader P; Beck J; Frey A; Schlegel PG; Hebarth H; Handgretinger R; Einsele H; Niemeyer C; Benda N; Faul C; Kanz L; Niethammer D; Klingebiel T
    Bone Marrow Transplant; 1998 Mar; 21(5):487-95. PubMed ID: 9535041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mixed chimerism after allogeneic bone marrow transplantation for leukemias.
    Bertheas MF; Lafage M; Blaise D; Stoppa AM; Viens P; Mannoni P; Maraninchi D
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():61-3. PubMed ID: 2390641
    [No Abstract]   [Full Text] [Related]  

  • 25. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Engraftment and chimerism, particularly of T- and B-cells, in children undergoing allogeneic bone marrow transplantation.
    Winiarski J; Mattsson J; Gustafsson A; Wester D; Borgström B; Ringdén O; Ljungman P; Dalianis T
    Pediatr Transplant; 1998 May; 2(2):150-6. PubMed ID: 10082448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mixed chimera converted into full donor chimera with powerful graft-versus-leukemia effects but no graft-versus-host disease after non T cell-depleted HLA-mismatched peripheral blood stem cell transplantation.
    Wu BY; Guo KY; Song CY; Yang ; Li D
    Bone Marrow Transplant; 2000 Sep; 26(6):691-3. PubMed ID: 11035376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Preliminary study of HLA haplotype matched and T-cell undepleted allogeneic bone marrow transplantation for treatment of leukemia].
    Ji S; Chen H; Wang H
    Zhonghua Xue Ye Xue Za Zhi; 2001 Aug; 22(8):408-10. PubMed ID: 11718090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic bone marrow transplantation with T cell-depleted partially matched related donors for advanced acute lymphoblastic leukemia in children and adults: a comparative matched cohort study.
    Fleming DR; Henslee-Downey PJ; Romond EH; Harder EJ; Marciniak E; Munn RK; Messino MJ; Macdonald JS; Bishop M; Rayens MK; Thompson JS; Foon KA
    Bone Marrow Transplant; 1996 Jun; 17(6):917-22. PubMed ID: 8807094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical trial depleting T lymphocytes from donor marrow for matched and mismatched allogeneic bone marrow transplants.
    Trigg ME; Billing R; Sondel PM; Exten R; Hong R; Bozdech MJ; Horowitz SD; Finlay JL; Moen R; Longo W
    Cancer Treat Rep; 1985 Apr; 69(4):377-86. PubMed ID: 3888387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of tolerance after haplocompatible T-depleted bone marrow transplantation.
    Merino A; Dror Y; Benkerrou M; Colombe BW; Cowan MJ
    Bone Marrow Transplant; 1993 Nov; 12(5):483-8. PubMed ID: 8298559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An immunosuppressive myeloablative preparative regimen adequate for matched sibling transplant, inadequate in histoincompatible, T cell-depleted marrow cells in leukemia.
    Kapoor N; Jung L; Bogardis C; DeBault L; Muneer R; Nitschke R; Good RA
    Transplant Proc; 1984 Dec; 16(6):1419-24. PubMed ID: 6239418
    [No Abstract]   [Full Text] [Related]  

  • 35. Complete donor T cell chimerism is accomplished in patients transplanted with bone marrow grafts containing a fixed low number of T cells.
    Verdonck LF; van Blokland WT; Bosboom-Kalsbeek EK; van Heugten HG; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1996 Aug; 18(2):389-95. PubMed ID: 8864451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protection from graft-versus-host disease in fully allogeneic chimeras by prior administration of T cell-depleted syngeneic bone marrow.
    Sykes M; Chester CH; Sachs DH
    Transplantation; 1988 Aug; 46(2):327-30. PubMed ID: 3043787
    [No Abstract]   [Full Text] [Related]  

  • 37. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
    Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
    Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of hematopoietic chimerism in patients with acute leukemia after allogeneic bone marrow transplantation: a prospective study.
    Choi SJ; Lee KH; Lee JH; Kim S; Chung HJ; Lee JS; Kim SH; Park CJ; Chi HS; Kim WK
    Bone Marrow Transplant; 2000 Aug; 26(3):327-32. PubMed ID: 10967574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.